Figure 5 Target lesion revascularisation (TLR) rates in 10 different RCTs with sirolimus (blue, from RAVEL to DIABETES), in eight RCTs with paclitaxel (green, from TAXUS I to ISAR‐DIABETES‐PES), and one with zotarolimus (red, ENDEAVOR).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.